Literature DB >> 12644925

Acute renal failure following deferoxamine overdose.

Latha Prasannan1, Joseph T Flynn, John E Levine.   

Abstract

A 17-year-old patient with sickle cell-beta thalassemia undergoing treatment with home iron chelation therapy inadvertently received ten times the recommended dose of intravenous deferoxamine. Acute renal failure (ARF) developed within hours. Immediate treatment with high-efficiency hemodialysis resulted in the prompt return of renal function after only one hemodialysis session. No long-term nephrotoxic effects of the deferoxamine overdose developed after more than 1 year of follow-up. Children with sickle cell disease who are on intravenous deferoxamine and their parents should be cautioned about the possibility of ARF with overdose due to malfunction of the pump and/or inadequate monitoring during treatment. ARF, should it occur in such children, appears to respond well to treatment with high-efficiency hemodialysis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12644925     DOI: 10.1007/s00467-002-1051-7

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  13 in total

1.  Case report 744. Deferoxamine-induced skeletal dysplasia.

Authors:  Z C Borenstein; C B Hyman; D L Rimoin; C L Chapman; R Lachman
Journal:  Skeletal Radiol       Date:  1992       Impact factor: 2.199

2.  Sensorimotor neurotoxicity associated with high-dose deferoxamine treatment.

Authors:  J E Levine; A Cohen; M MacQueen; M Martin; P J Giardina
Journal:  J Pediatr Hematol Oncol       Date:  1997 Mar-Apr       Impact factor: 1.289

3.  Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.

Authors:  G M Brittenham; P M Griffith; A W Nienhuis; C E McLaren; N S Young; E E Tucker; C J Allen; D E Farrell; J W Harris
Journal:  N Engl J Med       Date:  1994-09-01       Impact factor: 91.245

4.  Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy.

Authors:  P Cianciulli; D Sollecito; F Sorrentino; L Forte; E Gilardi; A Massa; G Papa; S Carta
Journal:  Kidney Int       Date:  1994-08       Impact factor: 10.612

5.  Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia.

Authors:  B A Davis; J B Porter
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

6.  Acute renal insufficiency occurring during intravenous desferrioxamine therapy.

Authors:  R Batey; J Scott; S Jain; S Sherlock
Journal:  Scand J Haematol       Date:  1979-03

7.  Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis.

Authors:  P Cianciulli; F Sorrentino; L Forte; M Palombi; G Papa; C Meloni; M Taccone Gallucci; C U Casciani
Journal:  Haematologica       Date:  1992 Nov-Dec       Impact factor: 9.941

8.  Ototoxicity in hemoglobinopathy patients chelated with desferrioxamine.

Authors:  L A Styles; E P Vichinsky
Journal:  J Pediatr Hematol Oncol       Date:  1996-02       Impact factor: 1.289

9.  The iron chelators desferrioxamine and 1-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro.

Authors:  J Y Jeremy; G J Kontoghiorghes; A V Hoffbrand; P Dandona
Journal:  Biochem J       Date:  1988-08-15       Impact factor: 3.857

10.  Acute changes in renal function associated with deferoxamine therapy.

Authors:  G Koren; Y Bentur; D Strong; E Harvey; J Klein; R Baumal; S P Spielberg; M H Freedman
Journal:  Am J Dis Child       Date:  1989-09
View more
  3 in total

1.  Acute renal failure following deferoxamine overdose.

Authors:  Salvatore Li Volti; Carmela Maccarone; Giovanni Li Volti; Maria A Romeo
Journal:  Pediatr Nephrol       Date:  2003-08-14       Impact factor: 3.714

Review 2.  Renal complications of beta-thalassemia major in children.

Authors:  Ashraf Bakr; Youssef Al-Tonbary; Ghada Osman; Rasha El-Ashry
Journal:  Am J Blood Res       Date:  2014-09-05

3.  Glomerular and Tubular Functions in Children and Adults with Transfusion-Dependent Thalassemia.

Authors:  Agageldi Annayev; Zeynep Karakaş; Serap Karaman; Altan Yalçıner; Alev Yılmaz; Sevinç Emre
Journal:  Turk J Haematol       Date:  2017-07-28       Impact factor: 1.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.